Supha Pharmachem Limited (BOM:539561)
India · Delayed Price · Currency is INR 0.2600
-0.0100 (-3.70%)
At close: Sep 11, 2026
Supha Pharmachem Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 105 | 734 | 10,937 | 2,655 | 499 | 158 | |
Market Cap Growth | -82.31% | -93.29% | 311.88% | 432.56% | 214.77% | 97.31% |
Enterprise Value | 10,967 | 2,497 | 10,944 | 2,650 | 490 | 216 |
Last Close Price | 0.26 | 1.27 | 18.93 | 4.60 | 0.86 | 0.27 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
PE Ratio | 1.39 | 34.46 | 33.42 | 48.94 | 46.26 | 32.97 |
PS Ratio | 0.02 | 0.18 | 0.27 | 0.52 | 0.10 | 0.18 |
PB Ratio | 0.10 | 1.67 | 25.46 | 25.62 | 10.10 | 4.11 |
P/TBV Ratio | 0.10 | 1.67 | 25.46 | 25.62 | 10.10 | 4.11 |
P/FCF Ratio | - | - | - | 12.98 | 4.44 | - |
P/OCF Ratio | - | - | - | 12.95 | 4.42 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
EV/Sales Ratio | 2.08 | 0.62 | 0.27 | 0.52 | 0.10 | 0.24 |
EV/EBITDA Ratio | 194.91 | 203.05 | 32.72 | 39.46 | 27.57 | 29.91 |
EV/EBIT Ratio | 195.59 | 209.65 | 32.77 | 40.36 | 28.77 | 32.62 |
EV/FCF Ratio | - | - | - | 12.95 | 4.36 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Debt / Equity Ratio | 10.34 | 26.01 | 1.34 | - | - | 2.72 |
Debt / EBITDA Ratio | 193.28 | 928.04 | 1.72 | - | - | 14.55 |
Net Debt / Equity Ratio | 10.33 | 25.97 | 1.31 | -2.11 | -0.29 | 2.51 |
Net Debt / EBITDA Ratio | 193.04 | 926.88 | 1.68 | -3.25 | -0.81 | 13.43 |
Net Debt / FCF Ratio | -1.08 | -1.00 | -0.76 | -1.07 | -0.13 | -0.94 |
Asset Turnover | 0.28 | 0.22 | 2.61 | 0.74 | 3.85 | 4.21 |
Inventory Turnover | 1.81 | 1.98 | 56.94 | 10.83 | 11.46 | 46.07 |
Quick Ratio | 0.44 | 0.46 | 0.48 | 0.17 | 0.35 | 1.01 |
Current Ratio | 1.07 | 1.03 | 1.02 | 1.01 | 1.02 | 1.59 |
Return on Equity (ROE) | 16.22% | 4.90% | 122.76% | 70.92% | 24.51% | 13.33% |
Return on Assets (ROA) | 0.19% | 0.04% | 1.35% | 0.60% | 0.81% | 1.93% |
Return on Invested Capital (ROIC) | 0.37% | 0.09% | 49.44% | - | 14.11% | 5.96% |
Return on Capital Employed (ROCE) | 5.30% | 2.70% | 77.70% | 63.30% | 34.50% | 4.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Earnings Yield | 116.89% | 2.90% | 2.99% | 2.04% | 2.16% | 3.03% |
FCF Yield | -9579.26% | -1546.43% | -6.78% | 7.70% | 22.53% | -64.72% |
Buyback Yield / Dilution | -9.07% | - | - | 0.12% | 0.03% | -0.14% |